BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25416631)

  • 1. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
    Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
    BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
    Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
    Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.
    Ostheimer C; Schweyer F; Reese T; Bache M; Vordermark D
    Oncol Lett; 2016 Nov; 12(5):3449-3456. PubMed ID: 27900019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
    Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
    BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
    Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
    Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
    Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
    J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.
    Takenaka M; Hanagiri T; Shinohara S; Yasuda M; Chikaishi Y; Oka S; Shimokawa H; Nagata Y; Nakagawa M; Uramoto H; So T; Yamada S; Tanaka F
    Clin Lung Cancer; 2013 May; 14(3):288-94. PubMed ID: 23122494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
    Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
    BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.
    Polat B; Kaiser P; Wohlleben G; Gehrke T; Scherzad A; Scheich M; Malzahn U; Fischer T; Vordermark D; Flentje M
    BMC Cancer; 2017 Jan; 17(1):6. PubMed ID: 28049456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
    Isa S; Kawaguchi T; Teramukai S; Minato K; Ohsaki Y; Shibata K; Yonei T; Hayashibara K; Fukushima M; Kawahara M; Furuse K; Mack PC
    J Thorac Oncol; 2009 Sep; 4(9):1104-10. PubMed ID: 19620934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
    Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin as a marker of weight loss in lung cancer.
    Karadag F; Gulen ST; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O
    Scand J Clin Lab Invest; 2011 Dec; 71(8):690-4. PubMed ID: 22017168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.
    Kerenidi T; Kazakou AP; Lada M; Tsilioni I; Daniil Z; Gourgoulianis KI
    Cancer Invest; 2016 Sep; 34(8):385-92. PubMed ID: 27624849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
    Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
    Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
    De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
    Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
    J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum osteopontin levels in small cell lung cancer.
    Xu C; Yuan Q; Wang W; Chi C; Zhang Q; Li L; Yang R; Wang Y
    BMC Pulm Med; 2020 Sep; 20(1):235. PubMed ID: 32873264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.